NCT02108119 is a Phase 2 clinical trial of Probiotics in Irritable Bowel Syndrome, sponsored by Probi AB.

Who is sponsoring NCT02108119?

NCT02108119 is sponsored by Probi AB.

What drugs are being tested in NCT02108119?

Interventions in NCT02108119: Probiotics, Control placebo.

What condition does NCT02108119 study?

NCT02108119 studies Irritable Bowel Syndrome.

Is NCT02108119 still recruiting?

NCT02108119 is currently completed. Last updated 16 June 2017.

Last reviewed 2017-06-16 · How we verify

NCT02108119

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Probiotics on Symptoms and Intestinal Flora in Patients With Irritable Bowel Syndrome

Completed Phase 2 Last updated 16 June 2017

What this trial tests

Phase 2 trial testing Probiotics in Irritable Bowel Syndrome in 197 participants. Completed in 30 November 2015.

Timeline

2 May 2014

Primary endpoint
30 November 2015

30 November 2015

Quick facts

Lead sponsor	Probi AB
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	197
Start date	2 May 2014
Primary completion	30 November 2015
Estimated completion	30 November 2015
Sites	1 location across Netherlands

Drugs / interventions tested

Probiotics — full drug profile →
Control placebo

Conditions studied

Irritable Bowel Syndrome — all drugs for Irritable Bowel Syndrome →

Sponsor

Probi AB — full company profile →

Who can join

Adults 18 to 70, any sex, with Irritable Bowel Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To demonstrate benefit of a probiotic product in adults with irritable bowel syndrome.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Probiotics

Trials testing the same drug.

NCT07470645 — Effects of Probiotic Supplementation on Stress and Anxiety in Students · NA · not yet recruiting
NCT06943235 — Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in th · Phase 2 · recruiting
NCT06827964 — Practice of Nutrition Package in Myanmar · NA · not yet recruiting
NCT06873165 — Development of Microbial Therapeutics for Metabolic-associated Fatty Liver Disease: From Mechanistic Investigations to C · NA · recruiting
NCT06583720 — Comparative Study Between Photodynamic Therapy with LED Associated with Probiotics in the Treatment of Halitosis · Phase 1 · recruiting

Other recruiting trials for Irritable Bowel Syndrome

Currently open trials in the same condition.

NCT07235228 — Effects of Vivatlac Synbiotic on Gut Micribiota of IBS Patients · NA · recruiting
NCT07421011 — Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 · Phase 1 · recruiting
NCT07360938 — Drug Interaction Potential of Pro-Inflammatory Conditions · recruiting
NCT06788444 — Efficacy of Esketamine for Patients With Irritable Bowel Syndrome · NA · recruiting
NCT07484412 — Efficacy and Safety of Encapsulated Bifidobacterium Longum BBH016 in Subjects With Lower Gastrointestinal Symptoms · NA · active not recruiting

Other Probi AB trials

Trials by the same sponsor.

NCT06444139 — Probiotic Intervention for Occasional Constipation · NA · completed
NCT05155449 — Probiotic Intervention for Gut Function · NA · completed
NCT04931082 — Probiotic Intervention for Stress and Cognition · NA · completed
NCT03284905 — Probiotic Intervention for Acute Stress · NA · completed
NCT03259997 — Efficacy of Probiotics on Physical Performance · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02108119 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Probi AB
Last refreshed: 16 June 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02108119.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing